BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat psychiatric and neurological disorders.
Our vision is to develop breakthrough non-hallucinogenic psychedelic derivatives with the therapeutic potential to treat wide range of mental health and neurological conditions that have a high unmet need.

Burdens call for alternatives in the landscape of options ….

Challenges Facing All Stakeholders in Mental Healthcare
People

Are struggling with increased occurrences of mental health issues

Health Providers

Are challenged to keep pace with more demands for better solutions

Insurance Providers

Are strained from pressures due to increasing number of patients

Governments

Are logging higher health care costs from rising mental health problems

Adult with Depression
0 %
Do Not Receive Mental Health Treatment2
Covid Mental Strain
0 %
US Adults Are Dealing with Anxiety & Depression1
Mental Health Spending
$ 0 Billion
Increase In Anxiety & Depression In Adults3
BetterLife Pharma’s lead product, BETR-001 (2-bromo-LSD), is a first-in-class, second-generation, non-hallucinogenic lysergic acid diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. Additionally, as a non-hallucinogenic compound, BETR-001 does not have the restrictions and regulatory hurdles imposed on psychedelics.
Competitive Advantages of BETR-001
COMPOUNDBETR-001PSILOCYBINLSDMDMA
CSA Schedule 1 Drug NoYesYesYes
Multiple Formal Human StudiesYesYesYesYes
Hallucinogenic EffectsNoYesYesLow/No
USDOJ List 1 Precursors NoYesYesYes
UN Convention Illicit Drug NoYesYesYes
Patient Self-AdministeredYesNoNoNo
Regulatory Hurdle(s)LowHighHighHigh
BETR-001 is a potential new therapy to treat debilitating psychiatric disorders with high unmet need, such as Major Depressive Disorder and Anxiety Disorders; as well as neurological disorders such as neuropathic pain.
potential-img

Pipeline and Indications Program

We are developing first-in-class, 2nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need
Our commitment, from inception to reception, is to deliver patient-centric medicines rooted on solid pharmacological principles and processes that deliver results.

Pipeline and Indications Program

We are developing first-in-class, 2nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need

Compound Name: BETR-001

Product Name: E559 [proprietary 2-bromo-LSD compound]

Delivery: Oral, Capsule

Description: AA first-in-class, non-hallucinogenic, second-generation LSD derivative. 

Indications: MDD, Anxiety, Neuropathic Pain

Patents: Issued and Pending

Compound Name: BETR-002

Product Name: Dihydrohonokiol-B (DHH-B)

Delivery: Oral Capsule

Description: A derivative of hydrohonokiol, a known anxiolytic compound. 

Indications: Benzodiazepine Dependency, Anxiety, Neurodegenerative disorders

Patents: Pending 

Pipeline

Program

 Discovery Preclinical IND Phase I Phase II Phase III
Major Depressive Disorder BETR-001
Anxiety Disorder BETR-001
Neuropathic Pain BETR-001
Benzodiazepine Dependency BETR-002

References

  1. https://www.nature.com/articles/d41586-021-00175-z
  2. https://mhanational.org/sites/default/files/2021%20State%20of%20Mental%20Health%20in%20America_0.pdf
  3. https://finance.yahoo.com/news/why-mental-health-care-in-america-is-so-shoddy-183448311.html

Clinical Process

Study Design

Customized & Protocol Based

Drug Development
Proactive & Data Driven
Trial Execution
Transparent & Compliant
Regulatory Submission
Complete & Timely

The unmet mental health footprint is immense. Our programs start and end with patients first, driving us for continuous solutions. We will expand our programs to address other indications, timely and progressively!

BetterLife also owns a drug candidate, for the treatment of viral infections such as COVID-19,
through its wholly owned subsidiary MedMelior.

Contact Us
Working together to Build a BetterLife for all.
REACH US

Working to Build a BetterLife, with innovate medicines.

 

Our work delivers patient-friendly medicines to rejuvenate and restore the health of the mind and the body.

 
Email us: ir@blifepharma.com
 

Follow us: